Label Changes for:
Surmontil (Trimipramine Maleate) Capsules
December 2012
Changes have been made to the CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)- December 2012
CONTRAINDICATIONS
Monoamine Oxidase Inhibitors (MAOIs)
- The use of MAOIs intended to treat psychiatric disorders….
Hypersensitivity to Tricyclic Antidepressants
- Cross-sensitivity between Surmontil and other dibenzazepines is a possibility.
